S1+ Paclitaxel (IV & IP) + Bevacizumab (IP) Versus S1+Oxaliplatin as First-line Treatment in Gastric Cancer With Malignant Ascites

Condition:   Metastatic Gastric Adenocarcinoma Interventions:   Drug: S1;   Drug: Paclitaxel;   Drug: Bevacizumab;   Drug: Oxaliplatin Sponsor:   China Medical University, China Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials